- Home
- XOMA vs ENGN Comparison
XOMA vs ENGN Comparison
Compare XOMA & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMA
- ENGN
- Stock Information
- Founded
- XOMA 1981
- ENGN 1999
- Country
- XOMA United States
- ENGN Canada
- Employees
- XOMA N/A
- ENGN N/A
- Industry
- XOMA Biotechnology: Pharmaceutical Preparations
- ENGN
- Sector
- XOMA Health Care
- ENGN
- Exchange
- XOMA Nasdaq
- ENGN Nasdaq
- Market Cap
- XOMA 355.6M
- ENGN 293.1M
- IPO Year
- XOMA N/A
- ENGN N/A
- Fundamental
- Price
- XOMA $30.21
- ENGN $7.63
- Analyst Decision
- XOMA Strong Buy
- ENGN Strong Buy
- Analyst Count
- XOMA 2
- ENGN 6
- Target Price
- XOMA $78.50
- ENGN $33.67
- AVG Volume (30 Days)
- XOMA 30.4K
- ENGN 99.5K
- Earning Date
- XOMA 11-07-2024
- ENGN 09-10-2024
- Dividend Yield
- XOMA N/A
- ENGN N/A
- EPS Growth
- XOMA N/A
- ENGN N/A
- EPS
- XOMA N/A
- ENGN N/A
- Revenue
- XOMA $21,606,000.00
- ENGN N/A
- Revenue This Year
- XOMA $488.61
- ENGN N/A
- Revenue Next Year
- XOMA $27.42
- ENGN N/A
- P/E Ratio
- XOMA N/A
- ENGN N/A
- Revenue Growth
- XOMA 389.82
- ENGN N/A
- 52 Week Low
- XOMA $14.33
- ENGN $4.42
- 52 Week High
- XOMA $33.78
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- XOMA 52.03
- ENGN 42.76
- Support Level
- XOMA $29.09
- ENGN $7.82
- Resistance Level
- XOMA $32.50
- ENGN $8.61
- Average True Range (ATR)
- XOMA 1.87
- ENGN 0.56
- MACD
- XOMA -0.17
- ENGN -0.19
- Stochastic Oscillator
- XOMA 49.29
- ENGN 1.18
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.